C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells

Leukemia

Volumn 26, Issue 2, 2012, Pages 303-311

  Satoh, Y ^a   Matsumura, I ^b   Tanaka, H ^b   Harada, H ^c   Harada, Y ^c   Matsui, K ^a   Shibata, M ^a   Mizuki, M ^a   Kanakura, Y ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

acute myeloid leukemia; DNA damage; GADD45A; myelodysplastic syndromes; RUNX1

Indexed keywords

DNA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; TRANSCRIPTION FACTOR RUNX1;

ATTENUATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW;

ANIMALS; CELL CYCLE PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 84856752060     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.202     Document Type: Review

References (39)

1. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003; 33: 153-160. (Pubitemid 43102857)
2. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-2990. (Pubitemid 28227550)
3. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022-3026. (Pubitemid 23162121)
4. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243-1248.
5. Harada Y, Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 2009; 220: 16-20.
6. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265-275. (Pubitemid 26042564)
7. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
8. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502-513. (Pubitemid 37328932)
9. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114: 5352-5361.
10. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175. (Pubitemid 29455388)
11. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10: 299-304. (Pubitemid 38667622)
12. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74. (Pubitemid 41039177)
13. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
14. Lindahl T, Barnes DE. Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 2000; 65: 127-133. (Pubitemid 32611934)
15. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374. (Pubitemid 32467046)
16. Kundu M, Compton S, Garrett-Beal L, Stacy T, Starost MF, Eckhaus M et al. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma. Blood 2005; 106: 3621-3624. (Pubitemid 41609202)
17. Liebermann DA, Hoffman B. Gadd45 in stress signaling. J Mol Signal 2008; 3: 15.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199. (Pubitemid 12073508)
19. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316-2324. (Pubitemid 38326252)
20. Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem 2008; 283: 30045-30056.
21. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101: 673-680. (Pubitemid 36077592)
22. Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995; 14: 341-350.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. (Pubitemid 28124064)
24. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24: 679-686.
25. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005; 65: 11704-11711. (Pubitemid 41821731)
26. Mori T, Nakane M, Hattori T, Matsunaga T, Ihara M, Nikaido O. Simultaneous establishment of monoclonal antibodies specific for either cyclobutane pyrimidine dimer or (6-4)photoproduct from the same mouse immunized with ultraviolet-irradiated DNA. Photochem Photobiol 1991; 54: 225-232.
27. Perugini M, Kok CH, Brown AL, Wilkinson CR, Salerno DG, Young SM et al. Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation. Leukemia 2009; 23: 729-738.
28. Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace Jr AJ. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem 1993; 268: 24385-24393. (Pubitemid 23335431)
29. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
30. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R et al. Genomic instability in Gadd45a-deficient mice. Nat Genet 1999; 23: 176-184. (Pubitemid 29455389)
31. Yamashita N, Osato M, Huang L, Yanagida M, Kogan SC, Iwasaki M et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 2005; 131: 495-507. (Pubitemid 43899649)
32. Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, Jansen M et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood 2008; 111: 2190-2199. (Pubitemid 351451533)
33. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112: 1751-1761. (Pubitemid 38063733)
34. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA. GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 2002; 192: 327-338. (Pubitemid 34827609)
35. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.
36. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR et al. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol 2000; 20: 3705-3714. (Pubitemid 30243916)
37. Gupta M, Gupta SK, Balliet AG, Hollander MC, Fornace AJ, Hoffman B et al. Hematopoietic cells from Gadd45a-and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene 2005; 24: 7170-7179. (Pubitemid 41679279)
38. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 47-53. (Pubitemid 40143686)
39. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndromeFthe mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405-414. (Pubitemid 47512182)